Skip to Content
Biotechnology

Virtual drug trials will let you join a test from the comfort of your own home

August 30, 2018

Stay-at-home trials are allowing more people to participate in test runs.

The past: Participants in drug trials previously had to spend a lot of time and money visiting research locations. That hassle contributes to a 30 percent dropout rate.

The future: Virtual trials have people do the work and testing themselves. “Because we bring trials to patients in their homes, we remove barriers, whether geography or time and inconvenience, that are preventing them from participating,” Belinda Tan, cofounder of Science 37, told Undark. A recent trial by AOBiome Therapeutics of an acne medication recruited people through social media, screened 8,000 candidates online, and conducted the research through traditional mail, e-mail, iPhone app, and videoconferencing.

Ups and downs: While virtual trials are cheaper and more convenient, it does make it harder to ensure that some tests are done consistently and properly, since many people don’t like injecting themselves.

This story first appeared in our daily tech newsletter, The Download. You can sign up here.

Deep Dive

Biotechnology

This startup wants to copy you into an embryo for organ harvesting

With plans to create realistic synthetic embryos, grown in jars, Renewal Bio is on a journey to the horizon of science and ethics.

This nanoparticle could be the key to a universal covid vaccine

Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.

How do strong muscles keep your brain healthy?

There’s a robust molecular language being spoken between your muscles and your brain.

The quest to show that biological sex matters in the immune system

A handful of immunologists are pushing the field to take attributes such as sex chromosomes, sex hormones, and reproductive tissues into account.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.